Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Roshan Katekar, Pragati Singh, Richa Garg, Saurabh Verma & Jiaur R. Gayen. (2022) Emerging nanotechnology based combination therapies of taxanes for multiple drug-resistant cancers. Pharmaceutical Development and Technology 27:1, pages 95-107.
Read now
Read now
Hong Yao, Junkai Liu, Shengtao Xu, Zheying Zhu & Jinyi Xu. (2017) The structural modification of natural products for novel drug discovery. Expert Opinion on Drug Discovery 12:2, pages 121-140.
Read now
Read now
Articles from other publishers (47)
Boyang Sun, Shuai Shao, Sanjana Ghosh, Jiexin Li, Xiaojie Wang, Changning Li, Breandan Quinn, Paschalis Alexandridis, Jonathan F. Lovell & Yumiao Zhang. (2023) Facile preparation of cabazitaxel-loaded nanoparticles directly lyophilized from dioxane一种用二氧六环制备紫杉醇冻干制剂的简易方法. Science China Materials 66:6, pages 2513-2522.
Crossref
Crossref
Yuxin Zhang, Jie Zhou, Xiaoting Chen, Zhiqian Li, Lei Gu, Dayi Pan, Xiuli Zheng, Qianfeng Zhang, Rongjun Chen, Hu Zhang, Qiyong Gong, Zhongwei Gu & Kui Luo. (2023) Modulating tumor-stromal crosstalk via a redox-responsive nanomedicine for combination tumor therapy. Journal of Controlled Release 356, pages 525-541.
Crossref
Crossref
M. H. Zalzala, W. S. Al-khfajy & R. A. Khaleel. (2023) Cytotoxic Effect of 6-Ethyl-Chenodeoxycholic Acid and Cabazitaxel on PC-3 Cells. Drug development & registration 12:1, pages 52-58.
Crossref
Crossref
Domenico Iacopetta, Jessica Ceramella, Noemi Baldino, Maria Sinicropi & Alessia Catalano. (2023) Targeting Breast Cancer: An Overlook on Current Strategies. International Journal of Molecular Sciences 24:4, pages 3643.
Crossref
Crossref
Astrid Hyldbakk, Karianne Giller Fleten, Sofie Snipstad, Andreas K.O. Åslund, Catharina de Lange Davies, Kjersti Flatmark & Yrr Mørch. (2023) Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models. Nanomedicine: Nanotechnology, Biology and Medicine 48, pages 102656.
Crossref
Crossref
Ji‐Zhao Xie, Huan‐Ji Xu, Qing Zhang, Zheng Wu, Xin‐Duo Wu, Xue‐Hua Li, Zhen‐Yuan Tan, Yun‐Feng Xie & Li Qiu. (2023) Semi‐Synthesis of Flavonoid Glycosides and Their Anti‐Inflammatory and Antitumor Activities towards Triple Negative Breast Cancer. Chemistry & Biodiversity 20:2.
Crossref
Crossref
Amit Bahl, William Wilson, Jessica Ball, Emily Renninson, Sidharth Dubey, Alicia Bravo, Emily Foulstone, Saiqa Spensley, Rebecca Bowen, Janine Mansi, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, Jeremy Braybrooke, Charles Comins, Vivek Mohan, Abigail Gee, Hannah Kirk, Alison Markham, Heidi Evans, Eve Watson, Mark Callaway, Sylvia Pearson, Allan Hackshaw & Mark Churn. (2022) Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer. The Breast 66, pages 69-76.
Crossref
Crossref
Karianne Giller Fleten, Astrid Hyldbakk, Caroline Einen, Sopisa Benjakul, Berit Løkensgard Strand, Catharina de Lange Davies, Ýrr Mørch & Kjersti Flatmark. (2022) Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery. Marine Drugs 20:12, pages 744.
Crossref
Crossref
Vijay Patil, Sravan Kumar, Vanita Noronha, Nandini Menon, Kavita Prakash Nawale, Mitali Alone, Gopichand Waratkar, Sachin Dhumal, Atanu Bhattacharjee & Kumar Prabhash. (2022) Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. Oral Oncology 134, pages 106085.
Crossref
Crossref
Vikas, Abhishesh Kumar Mehata, M. Nikitha Lakshmi Suseela, Chittaranjan Behera, Pooja Kumari, Sanjeev Kumar Mahto & Madaswamy S. Muthu. (2022) Chitosan-alginate nanoparticles of cabazitaxel: Design, dual-receptor targeting and efficacy in lung cancer model. International Journal of Biological Macromolecules 221, pages 874-890.
Crossref
Crossref
Andreas K. O. Åslund, Rob J. Vandebriel, Fanny Caputo, Wim H. de Jong, Christiaan Delmaar, Astrid Hyldbakk, Emilie Rustique, Ruth Schmid, Sofie Snipstad, Isabelle Texier, Kai Vernstad & Sven Even F. Borgos. (2022) A comparative biodistribution study of polymeric and lipid-based nanoparticles. Drug Delivery and Translational Research 12:9, pages 2114-2131.
Crossref
Crossref
Kobisha Rajeswaran, Kaitlin Muzio, Juan Briones, Mary Jane Lim-Fat, Chia-Lin Tseng, Martin Smoragiewicz, Jay Detsky & Urban Emmenegger. (2022) Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis. Journal of Clinical Medicine 11:14, pages 4165.
Crossref
Crossref
Manmeet Kaur, Mandeep Kaur, Tania Bandopadhyay, Aditi Sharma, Anu Priya, Arvind Singh & Bubun Banerjee. (2022) Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. Physical Sciences Reviews 0:0.
Crossref
Crossref
Asuman Deveci Ozkan, Gamze Guney Eskiler, Suleyman Kaleli & Elvan Sahin. (2021) Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro. Molecular Biology Reports 49:2, pages 1261-1271.
Crossref
Crossref
Alja Zottel, Ivana Jovčevska, Neja Šamec & Radovan Komel. (2021) Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Critical Reviews in Oncology/Hematology 160, pages 103283.
Crossref
Crossref
Yathsoeung Ho, Nungruthai Suphrom, Krai Daowtak, Pachuen Potup, Yordhathai Thongsri & Kanchana Usuwanthim. (2020) Anticancer Effect of Citrus hystrix DC. Leaf Extract and Its Bioactive Constituents Citronellol and, Citronellal on the Triple Negative Breast Cancer MDA-MB-231 Cell Line. Pharmaceuticals 13:12, pages 476.
Crossref
Crossref
Xingjian Zhai & Yassine El Hiani. (2020) Getting Lost in the Cell–Lysosomal Entrapment of Chemotherapeutics. Cancers 12:12, pages 3669.
Crossref
Crossref
Wamidh H. Talib, Izzeddin Alsalahat, Safa Daoud, Reem Fawaz Abutayeh & Asma Ismail Mahmod. (2020) Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation. Molecules 25:22, pages 5319.
Crossref
Crossref
Angelos Koutras, Flora Zagouri, Georgia-Angeliki Koliou, Elizabeth Psoma, Ioannis Chryssogonidis, Georgios Lazaridis, Dimitrios Tryfonopoulos, Athanasios Kotsakis, Eleni Res, Nikolaos K. Kentepozidis, Evangelia Razis, Amanda Psyrri, Georgios Koumakis, Haralabos P. Kalofonos, Meletios A. Dimopoulos & George Fountzilas. (2020) Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial. British Journal of Cancer 123:3, pages 355-361.
Crossref
Crossref
Zhen Zhao, Yuanke Li, Hao LiuAkshay JainPratikkumar Vinodchandra PatelKun Cheng. (2020) Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. Science Advances 6:29.
Crossref
Crossref
Boyang Sun, Upendra Chitgupi, Changning Li, Jasmin Federizon, Changjie Zhang, Donna M. Ruszaj, Aida Razi, Joaquin Ortega, Sriram Neelamegham, Yumiao Zhang & Jonathan F Lovell. (2019) Surfactant‐Stripped Cabazitaxel Micelles Stabilized by Clotrimazole or Mifepristone. Advanced Therapeutics 3:3, pages 1900161.
Crossref
Crossref
Martina Pagliuca, Carlo Buonerba, Karim Fizazi & Giuseppe Di Lorenzo. (2019) The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs 79:4, pages 381-400.
Crossref
Crossref
Gianluca Ingrosso, Beatrice Detti, Daniele Scartoni, Andrea Lancia, Irene Giacomelli, Muhammed Baki, Giulio Carta, Lorenzo Livi & Riccardo Santoni. (2018) Current therapeutic options in metastatic castration-resistant prostate cancer. Seminars in Oncology 45:5-6, pages 303-315.
Crossref
Crossref
Hai Tao, Xiaoyan Tang, Lin Jin, Yingchun Zhao, Yue Luo, Zheng Zhang, Lin Cai, Fenghua Tao & Weichun Guo. (2018) Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice. Biochemical and Biophysical Research Communications 505:2, pages 372-377.
Crossref
Crossref
Boyang Sun, Robert M. Straubinger & Jonathan F. Lovell. (2018) Current taxane formulations and emerging cabazitaxel delivery systems. Nano Research 11:10, pages 5193-5218.
Crossref
Crossref
Rajesh R. Nair, Debbie Piktel, Werner J. Geldenhuys & Laura F. Gibson. (2018) Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia. Leukemia Research 72, pages 59-66.
Crossref
Crossref
Peter E. Manley, Tanya Trippett, Amy A. Smith, Margaret E. Macy, Sarah E.S. Leary, Jessica Boklan, Kenneth J. Cohen, Stewart Goldman, Lindsay B. Kilburn, Girish Dhall, Jeanne Devin, Cynthia E. Herzog, Sonia Partap, Floris Fauchet, Emmy Badreddine, John P. Bernard & Susan N. Chi. (2018) A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatric Blood & Cancer 65:9, pages e27217.
Crossref
Crossref
Tianyang Ren, Jingxin Gou, Wanxiao Sun, Xiaoguang Tao, Xinyi Tan, Puxiu Wang, Yu Zhang, Haibing He, Tian Yin & Xing Tang. (2018) Entrapping of Nanoparticles in Yeast Cell Wall Microparticles for Macrophage-Targeted Oral Delivery of Cabazitaxel. Molecular Pharmaceutics 15:7, pages 2870-2882.
Crossref
Crossref
Ana Seca & Diana Pinto. (2018) Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application. International Journal of Molecular Sciences 19:1, pages 263.
Crossref
Crossref
Rodrigo Esaki Tamura, Igor Vieira de Luna, Marlous Gomes Lana & Bryan E Strauss. (2018) Improving adenoviral vectors and strategies for prostate cancer gene therapy. Clinics 73, pages e476s.
Crossref
Crossref
Tianyang Ren, Qian Wang, Ying Xu, Lin Cong, Jingxin Gou, Xiaoguang Tao, Yu Zhang, Haibing He, Tian Yin, Haotian Zhang, Yan Zhang & Xing Tang. (2018) Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles. Journal of Controlled Release 269, pages 423-438.
Crossref
Crossref
Amit Joshi, Vijay Patil, Vanita Noronha, Sachin Dhumal, Nikhil Pande, Arun Chandrasekharan, Siddharth Turkar, Hollis DSouza, Sameer Shrirangwar, Abhishek Mahajan, Supreeta Arya, Shashikant Juvekar, Atanu BhattaCharjee & Kumar Prabhash. (2017) Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. Oral Oncology 75, pages 54-60.
Crossref
Crossref
Sofie Snipstad, Sigrid Berg, Ýrr Mørch, Astrid Bjørkøy, Einar Sulheim, Rune Hansen, Ingeborg Grimstad, Annemieke van Wamel, Astri F. Maaland, Sverre H. Torp & Catharina de Lange Davies. (2017) Ultrasound Improves the Delivery and Therapeutic Effect of Nanoparticle-Stabilized Microbubbles in Breast Cancer Xenografts. Ultrasound in Medicine & Biology 43:11, pages 2651-2669.
Crossref
Crossref
Gregoriy Smiyun, Olga Azarenko, Herbert Miller, Alexander Rifkind, Nichole E. LaPointe, Leslie Wilson & Mary Ann Jordan. (2017) βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel. Cancer Chemotherapy and Pharmacology 80:1, pages 151-164.
Crossref
Crossref
María José Vallejo, Lizeth Salazar & Marcelo Grijalva. (2017)
Oxidative Stress Modulation and ROS-Mediated Toxicity in Cancer: A Review on
In Vitro
Models for Plant-Derived Compounds
. Oxidative Medicine and Cellular Longevity 2017, pages 1-9.
Crossref
Crossref
Ellen S de Morrée, René Böttcher, Robert J van Soest, Ashraf Aghai, Corrina M de Ridder, Alice A Gibson, Ron HJ Mathijssen, Herman Burger, Erik AC Wiemer, Alex Sparreboom, Ronald de Wit & Wytske M van Weerden. (2016) Loss of SLCO1B3 drives taxane resistance in prostate cancer. British Journal of Cancer 115:6, pages 674-681.
Crossref
Crossref
Per Kongsted, Inge M. Svane, Henriette Lindberg, Rasmus Bisbjerg, Gedske Daugaard & Lisa Sengeløv. (2016) Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer. Anti-Cancer Drugs 27:7, pages 695-701.
Crossref
Crossref
Begoña Mellado, Natalia Jimenez, Mercedes Marin-Aguilera & Oscar Reig. (2016) Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. Clinical Genitourinary Cancer 14:4, pages 265-270.
Crossref
Crossref
Nader Al Nakouzi, Chris Kedong Wang, Eliana Beraldi, Wolfgang Jager, Susan Ettinger, Ladan Fazli, Lucia Nappi, Jennifer Bishop, Fan Zhang, Anne Chauchereau, Yohann Loriot & Martin Gleave. (2016) Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Molecular Medicine 8:7, pages 761-778.
Crossref
Crossref
Ellen de Morrée, Robert van Soest, Ashraf Aghai, Corrina de Ridder, Peter de Bruijn, Inge Ghobadi Moghaddam-Helmantel, Herman Burger, Ron Mathijssen, Erik Wiemer, Ronald de Wit & Wytske van Weerden. (2016) Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. The Prostate 76:10, pages 927-936.
Crossref
Crossref
Byung Kang, Oh-Kyoung Kwon, Ho Chung, Wansik Yu & Jong Kim. (2016) Taxanes in the Treatment of Advanced Gastric Cancer. Molecules 21:5, pages 651.
Crossref
Crossref
Ignacio Duran, Carlos Hagen, José Ángel Arranz, María Apellaniz-Ruiz, Begoña Pérez-Valderrama, Nuria Sala, Nuria Lainez, Xavier García-Del Muro, Esther Noguerón, Miguel Ángel Climent, Pablo Maroto, Albert Font, Jesús García-Donas, Enrique Gallardo, Pilar López-Criado, Aránzazu González Del Alba, María Isabel Sáez, Sergio Vázquez, Raquel Luque & Cristina Rodríguez-Antona. (2016) SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. Pharmacogenomics 17:5, pages 463-471.
Crossref
Crossref
L. Prieto-Torres, M. Llamas-Velasco, S. Machan, R. Haro, S. de Asis, M. Carmo, A. Loredo, C. del Puerto, I. Fried, W. Kempf, L. Cerroni & L. Requena. (2016) Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy. Journal of the European Academy of Dermatology and Venereology 30:4, pages 638-644.
Crossref
Crossref
Ergun Karavelioglu, Yucel Gonul, Hasan Aksit, Mehmet Gazi Boyaci, Mustafa Karademir, Nejdet Simsek, Mustafa Guven, Tugay Atalay & Usame Rakip. (2016) Cabazitaxel causes a dose-dependent central nervous system toxicity in rats. Journal of the Neurological Sciences 360, pages 66-71.
Crossref
Crossref
Michael Kolinsky, Niven Mehra & Johann S. de Bono. 2016. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
187
214
.
C. Patrick Reynolds, Min H. Kang, John M. Maris, E. Anders Kolb, Richard Gorlick, Jianrong Wu, Raushan T. Kurmasheva, Peter J. Houghton & Malcolm A. Smith. (2015) Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 62:11, pages 1897-1905.
Crossref
Crossref
Aurelius Omlin, Oliver Sartor, Christian Rothermundt, Richard Cathomas, Johann S. De Bono, Liji Shen, Zhen Su & Silke Gillessen. (2015) Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clinical Genitourinary Cancer 13:4, pages e205-e208.
Crossref
Crossref